Across TCGA pan-cancer cohorts, TMEM222 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM222 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM222 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM222 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, GBM, and LSCC are the cancer types where TMEM222 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.769	0.523	.002	43	view →
GBM	OS	Median	All	0.902	0.731	.001	19	view →
LSCC	DFS	Quartile	II,III,IV	0.438	0.908	.004	14	view →
LUAD	OS	Tertile	III,IV	0.787	0.211	.004	10	view →
PDAC	DFS	Quartile	All	0.377	0.639	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TMEM222 tumor-vs-normal RNA expression · all TMEM222 data types